Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox Pharmaceutical's updated review of safety data for its ongoing multi-center phase II trial evaluating its lead drug candidate for the treatment of benign prostatic hyperplasia, NX-1207, has revealed no serious drug side effects.
Subscribe to our email newsletter
NX-1207 has completed two earlier phase I and II trials where the drug produced on average over 23% prostate shrinkage in one month with minimal side effects. Overall there have been no sexual side effects, and a better side effect profile compared to existing drugs.
The symptomatic improvement in earlier trials reached 10 points on the BPH symptom score, which is far superior to available drugs, and compares to invasive and surgical treatments.
Nymox also reported in January 2006 that the independent data monitoring committee for the trial of NX-1207 had given a positive recommendation based on evaluation of the efficacy and safety data at that point in time.
BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.